Oculis Holding AG (OCS) Net Income towards Common Stockholders (2022 - 2026)
Quarterly Net Income towards Common Stockholders changed 0.46% to -$37.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$21.0 billion through Mar 2026, up 9.94% year-over-year, with the annual reading at -$124.3 million for FY2025, 26.45% down from the prior year.
Oculis Holding AG's Net Income towards Common Stockholders history spans 5 years, with the latest figure at -$37.1 million for Q1 2026.
- Net Income towards Common Stockholders came in at -$37.1 million for Q1 2026, down from $72.7 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $72.7 million in Q4 2025 to a low of -$23.3 billion in Q3 2024.
- The 5-year median for Net Income towards Common Stockholders is -$21.5 million (2023), against an average of -$2.8 billion.
- Year-over-year, Net Income towards Common Stockholders plummeted 116344.35% in 2024 and then skyrocketed 318.67% in 2025.
- Oculis Holding AG's Net Income towards Common Stockholders stood at -$9.6 million in 2022, then crashed by 47.68% to -$14.1 million in 2023, then plummeted by 135.51% to -$33.3 million in 2024, then surged by 318.67% to $72.7 million in 2025, then plummeted by 151.01% to -$37.1 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Net Income towards Common Stockholders are -$37.1 million (Q1 2026), $72.7 million (Q4 2025), and -$21.0 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.63 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | -37.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.09 Mn |
| Dec 31, 2025 | 72.72 Mn |
| Sep 30, 2025 | -21.04 Bn |
| Jun 30, 2025 | -30.71 Mn |
| Mar 31, 2025 | -36.93 Mn |
| Dec 31, 2024 | -33.25 Mn |
| Sep 30, 2024 | -23.26 Bn |
| Jun 30, 2024 | -22.98 Mn |
| Mar 31, 2024 | -18.37 Mn |
| Dec 31, 2023 | -14.12 Mn |
| Sep 30, 2023 | -19.98 Mn |
| Jun 30, 2023 | -14.07 Mn |
| Mar 31, 2023 | -49.48 Mn |
| Dec 31, 2022 | -9.56 Mn |
| Sep 30, 2022 | -10.29 Mn |
| Jun 30, 2022 | -12.73 Mn |